Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study (original) (raw)

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis

Kim Papp

British Journal of Dermatology, 2013

View PDFchevron_right

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two, randomised, placebo-controlled, Phase 3 trials

Pedro Miranda

The British journal of dermatology, 2015

View PDFchevron_right

Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis

Stefania Madonna

Journal of Immunology Research

View PDFchevron_right

The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study

Tsen-fang Tsai

Journal of dermatological science, 2017

View PDFchevron_right

Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial

Kim Papp

The Journal of dermatology, 2017

View PDFchevron_right

Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial

Kim Papp

BMC dermatology, 2016

View PDFchevron_right

Tofacitinib for the treatment of moderate-to-severe psoriasis

Maria Sole Chimenti

Expert Review of Clinical Immunology, 2015

View PDFchevron_right

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

Fernando Valenzuela

Lancet, 2015

View PDFchevron_right

Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis

Kim Papp

CPT: Pharmacometrics & Systems Pharmacology, 2013

View PDFchevron_right

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors

Valderilio F Azevedo

The New England journal of medicine, 2017

View PDFchevron_right

Do Patients and Physicians Agree in Their Assessment of the Severity of Psoriasis ? Insights from Tofacitinib Phase 3 Clinical Trials

Lotus Mallbris

2015

View PDFchevron_right

A randomized phase 2b trial of baricitinib, an oral Janus kinase ( JAK ) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis

Kim Papp

British Journal of Dermatology, 2016

View PDFchevron_right

Tofacitinib in patients with moderate to severe chronic plaque psoriasis: 2-year efficacy and safety in an open-label long-term extension study

Tsen-fang Tsai

Journal of the American Academy of Dermatology, 2016

View PDFchevron_right

Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health‐related quality of life from two randomized phase 3 studies

Kim Papp

Journal of the European Academy of Dermatology and Venereology, 2020

View PDFchevron_right

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial

Mary Bachinsky

British Journal of Dermatology, 2015

View PDFchevron_right

Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient‐reported outcomes from a Phase 3 study

Jocelyne Papacharalambous

Journal of the European Academy of Dermatology and Venereology, 2016

View PDFchevron_right

IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood

Mayte Suarez-Farinas

The Journal of investigative dermatology, 2014

View PDFchevron_right

A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies

Joseph Cappelleri

BMC Dermatology

View PDFchevron_right

JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis

Leeyen Hsu

Journal of Immunology Research, 2014

View PDFchevron_right

Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment

Mayte Suarez-Farinas

Journal of Investigative Dermatology, 2017

View PDFchevron_right

Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience

Tsen-fang Tsai

Dermatology and Therapy

View PDFchevron_right

Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions

James Krueger

Journal of Investigative Dermatology, 2010

View PDFchevron_right

Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis

Naresh Punwani

Journal of the American Academy of Dermatology, 2012

View PDFchevron_right

Psoriasis: A STAT3-Centric View

Enzo Calautti

International Journal of Molecular Sciences, 2018

View PDFchevron_right

Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials

Valderilio F Azevedo

Clinical Rheumatology, 2021

View PDFchevron_right

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

Oliver Fitzgerald

Rheumatology and therapy, 2020

View PDFchevron_right

Immunohistochemical study of janus kinase 1/signal transducer and activator of transcription 3 in psoriasis vulgaris

Rehab Samaka

Clinical, Cosmetic and Investigational Dermatology, 2019

View PDFchevron_right

An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data

Huifeng Yun

Drug Safety, 2020

View PDFchevron_right

Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies

Ana-maria Orbai

BMC Rheumatology

View PDFchevron_right